Overview

PK,PD,Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Gemcitabine and Oxaliplatin for the Treatment of Patients With Relapsed/Refractory Diffuse Large B Cell Non-Hodgkin's Lymphoma

Status:
Terminated

Trial end date:
2021-03-12

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the safety and tolerability of MT-3724 in combination with gemcitabine and oxaliplatin (GEMOX) in subjects with relapsed or refractory B-Cell NHL.

Phase:

Phase 2

Details

Lead Sponsor:

Molecular Templates, Inc.

Treatments:

Gemcitabine
Oxaliplatin